Silk Road Medical Stock Forecast, Price & News

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Silk Road Medical in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" Silk Road Medical stock.
View analyst ratings for Silk Road Medical or view top-rated stocks.

5 equities research analysts have issued 1-year price targets for Silk Road Medical's stock. Their SILK stock forecasts range from $33.00 to $66.00. On average, they expect Silk Road Medical's stock price to reach $50.00 in the next twelve months. This suggests a possible upside of 26.2% from the stock's current price.
View analysts' price targets for Silk Road Medical or view top-rated stocks among Wall Street analysts.

Silk Road Medical's stock was trading at $42.61 at the beginning of 2022. Since then, SILK shares have decreased by 7.0% and is now trading at $39.63.
View the best growth stocks for 2022 here.

Silk Road Medical is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Silk Road Medical.

Silk Road Medical, Inc (NASDAQ:SILK) posted its quarterly earnings results on Wednesday, May, 4th. The company reported ($0.48) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.41) by $0.07. The company earned $28 million during the quarter, compared to analyst estimates of $27.10 million. Silk Road Medical had a negative net margin of 51.93% and a negative trailing twelve-month return on equity of 67.38%. Silk Road Medical's revenue for the quarter was up 39.7% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.31) EPS.
View Silk Road Medical's earnings history.

Silk Road Medical updated its FY 2022 earnings guidance on Monday, May, 16th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $127.00 million-$132.00 million, compared to the consensus revenue estimate of $129.54 million.

Some companies that are related to Silk Road Medical include Inspire Medical Systems (INSP), Penumbra (PEN), Integra LifeSciences (IART), ICU Medical (ICUI), Inari Medical (NARI), Tandem Diabetes Care (TNDM), iRhythm Technologies (IRTC), Haemonetics (HAE), Merit Medical Systems (MMSI), Axonics (AXNX), NuVasive (NUVA), Glaukos (GKOS), Beauty Health (SKIN), AtriCure (ATRC) and Nevro (NVRO).
View all of SILK's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Silk Road Medical investors own include Raytheon Technologies (RTX), Procter & Gamble (PG), Abbott Laboratories (ABT), Cisco Systems (CSCO), Pfizer (PFE), Edwards Lifesciences (EW), (HON), CSX (CSX), Thermo Fisher Scientific (TMO) and Alibaba Group (BABA).

(SILK) raised $75 million in an IPO on Thursday, April 4th 2019. The company issued 4,700,000 shares at $15.00-$17.00 per share. J.P. Morgan and BofA Merrill Lynch acted as the underwriters for the IPO and BMO Capital Markets and Stifel were co-managers.

Silk Road Medical trades on the NASDAQ under the ticker symbol "SILK."

Silk Road Medical's stock is owned by many different institutional and retail investors. Top institutional shareholders include Wasatch Advisors Inc. (11.71%), Vanguard Group Inc. (8.67%), Capital World Investors (7.95%), BlackRock Inc. (7.32%), Deerfield Management Company L.P. Series C (6.17%) and Clearbridge Investments LLC (3.91%). Company insiders that own Silk Road Medical stock include Andrew S Davis, Andrew S Davis, Erica J Rogers, Erica J Rogers, Jack W Lasersohn, Lucas W Buchanan, Lucas W Buchanan, Pincus & Co Warburg and Richard Ruedy.
View institutional ownership trends for Silk Road Medical.

SILK stock was sold by a variety of institutional investors in the last quarter, including Capital World Investors, Granahan Investment Management LLC, Northern Trust Corp, TimesSquare Capital Management LLC, Rhenman & Partners Asset Management AB, Bank Julius Baer & Co. Ltd Zurich, Goldman Sachs Group Inc., and First Trust Advisors LP. Company insiders that have sold Silk Road Medical company stock in the last two years include Andrew S Davis, Erica J Rogers, Jack W Lasersohn, Lucas W Buchanan, and Richard Ruedy.
View insider buying and selling activity for Silk Road Medical or view top insider-selling stocks.

SILK stock was acquired by a variety of institutional investors in the last quarter, including Deerfield Management Company L.P. Series C, Wasatch Advisors Inc., American Century Companies Inc., Novo Holdings A S, Massachusetts Financial Services Co. MA, Next Century Growth Investors LLC, Bellevue Group AG, and Landscape Capital Management L.L.C..
View insider buying and selling activity for Silk Road Medical or or view top insider-buying stocks.

Shares of SILK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of SILK stock can currently be purchased for approximately $39.63.

Silk Road Medical (NASDAQ:SILK) has a market capitalization of $1.39 billion and generates $101.47 million in revenue each year. The company earns $-49.81 million in net income (profit) each year or ($1.61) on an earnings per share basis.

Silk Road Medical employs 352 workers across the globe.

Silk Road Medical's mailing address is 1213 INNSBRUCK DR., SUNNYVALE CA, 94089. The official website for Silk Road Medical is www.silkroadmed.com. The company can be reached via phone at (408) 720-9002, via email at [email protected], or via fax at 408-720-9013.